Navigation Links
Orion Pharma Selects ChemDiv as A Partner in Drug Discovery Services
Date:11/30/2007

SAN DIEGO, Nov. 30 /PRNewswire/ -- ChemDiv, Inc. and Orion Pharma today announced that Orion has chosen ChemDiv as a discovery partner in small molecule therapeutics for Orion's priority targets.

Under the terms of the agreement, ChemDiv will deploy the Discovery outSource(TM) platform for Orion's discovery program, including the world's largest commercially available chemical library, proprietary rational design, assay development, and bioscreening. ChemDiv will screen rationally designed chemical libraries against Orion's proprietary targets, and Orion will select hit series for subsequent lead optimization. Financial terms and identity of drug targets were not disclosed. The agreement provides options for expanding the discovery partnership.

"I am very satisfied with the commitment and exchange of information in our joint effort. We have a good basis for success," said Dr. Ari Koivisto, Orion's contact person in the collaboration. "Our partnership with ChemDiv complements our in-house discovery effort in this particular project," stated Dr. Antti Haapalinna, Director of Nonclinical R&D, Orion Pharma, Orion Corporation.

"We are delighted to offer discovery services to Orion Pharma in this partnership. We are especially pleased with the constructive dialog with Orion R&D, based on our mutual understanding and shared goals. Based on ChemDiv's diligence and track record, we are confident of success and look forward to expansion of this collaboration in the near future," commented Nikolay Savchuk, President and CEO of ChemDiv, Inc.

About Orion Corporation

Orion Corporation (OMX: ORNAV, ORNBV) is one of the leading pharmaceutical companies in the northern Europe. Orion develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global markets. Pharmaceuticals generate about 95% of the Group's net sales, of which proprietary patented pharmaceutical innovations contribute a consi
'/>"/>

SOURCE ChemDiv, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Orion ICG, LLC Announces Acquisition of Cumberland Therapy Services, Inc.
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... Va., April 23, 2014 The American Society for ... "The Role of Postoperative Radiation Therapy for Endometrial ... use of adjuvant radiation therapy in the treatment ... published in the May-June 2014 issue of ... practice journal of ASTRO. The full-length guideline is ...
(Date:4/23/2014)... researchers have developed a way to detect and measure ... gold particles with tails of synthetic DNA., A team ... engineering, used gold nanoparticles to target and bind to ... splice variants, which can indicate the presence and stage ... variants in a cell can be determined by examining ...
(Date:4/23/2014)... compound that targets an important brain receptor has a ... including relapse behavior, a University at Buffalo animal study ... this may be a novel lead compound for treating ... UB research was published as an online preview article ... study, the compound, RO5263397, severely blunted a broad range ...
(Date:4/23/2014)... New Rochelle, NY, April 23, 2014Men whose testosterone falls ... dysfunction and to be overweight and have heart disease ... designed to identify testosterone-deficient men for further testing and ... Journal of Men,s Health , a peer-reviewed publication from ... free on the Journal of Men,s Health ...
(Date:4/23/2014)... In science, "simple and accessible detection methods that ... the resolution of a single cell inside that ... chemical engineer Chang Lu. , In the Royal ... Lu has announced that he and his coworkers ... subcellular location of a protein ( Chem. Sci. ...
Breaking Medicine News(10 mins):Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2
... , SAN DIEGO, Dec. 2 US Farms, ... and Wellness products, is pleased to announce it will be ... Calif., at the Oakland Zoo on December 11-20, 2009. , ... at 877-90-FARMS or visit http://cookswareafaire.com , Victor Brandstetter, ...
... , American Red Cross also ... WASHINGTON, Dec. 2 The Hewlett-Packard Company Foundation has contributed ... Red Cross disaster response. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) ... Philippine communities affected by typhoons in September and October. Other ...
... , , NASHVILLE, Tenn., Dec. 2 ... development company, has appointed Pearson Talbert as chief development ... Talbert will provide leadership and vision to the sales ... help hospitals grow revenues through employer partnerships and physician ...
... , BELLEVUE, Wash., ... leading online retailer of health, beauty, vision and pharmacy products ... China, India, and Brazil, plus 50 additional countries worldwide. More ... beauty and wellness products on http://international.drugstore.com with pricing ...
... the gene could be linked to life span in males ... affect life span in humans and other mammals and could ... Japanese scientists say. , The researchers found that mice created ... average of 186 days longer than mice created from the ...
... not advised, expert says , WEDNESDAY, Dec. 2 (HealthDay ... their heart might be helping their eyes as well. ... what they described as a modest benefit for aspirin ... that destroys sharp, central vision. , "The data indicate ...
Cached Medicine News:Health News:US Farms, Inc. Showcasing Aloe365(TM) Product Line at Cook'sware A'faire at Oakland Zoo 2Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 2Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 3Health News:Aegis Health Group Hires Pearson Talbert as Chief Development Officer 2Health News:drugstore.com Continues Global Sales Expansion to More Than 3.5 Billion International Consumers 2Health News:Sperm Gene May Cause Men's Longevity Disadvantage 2Health News:In Women, Aspirin Might Ward Off Eye Trouble 2
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Cystic Fibrosis Society Conference, MONMOUTH JUNCTION, N.J., ... from a Phase II clinical trial on its ... is being developed for the treatment of cystic ... the bacterium Pseudomonas,aeruginosa. The Phase II data indicated ...
... Conn., June 13 VION,PHARMACEUTICALS, INC. (Nasdaq: ... conducted Phase II trial of its lead anticancer ... (AML) and high-risk myelodysplastic syndromes (MDS) had been,presented ... Association (EHA),at the Bella Center in Copenhagen, Denmark. ...
Cached Medicine Technology:Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections 2Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections 3Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections 4Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections 5Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting 2Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting 3Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting 4
5.5 mm disk shape burr. Diamond coated tip. Use with E0824 B handle....
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Medium 23 mm. Overall length: 3.9 inches....
Abrupt taper 2 mm from the end, then more gradual taper so that quick dilation of the punctum is obtained. Stainless steel. Round knurled with polished finish. Overall length: 5.5 inches....
Double ended dilator probes with gentle curve. Stainless steel. Round knurled handle with polished finish. Overall length: 5.3 inches....
Medicine Products: